FDA Authorizes Cybin Device To Quantify Psychedelics' Effects On The Brain

This article was originally published on Psychedelic Spotlight and appears here with permission.

"This study of ketamine’s psychedelic effects while wearing headgear equipped with sensors to record brain activity could open up new frontiers of understanding," says Cybin's chief clinical officer.

We may be on a new frontier of understanding for psychedelic therapies, with the Food and Drug Administration (FDA) authorizing a neuroimaging device that may allow researchers to quantify psychedelics’ effects on the brain, in real-time.

The Kernel Flow device, developed by neurotech company Kernel in partnership with Canadian biotechnology company Cybin, will be used in a feasibility study to measure ketamine’s psychedelic effects on the brain, specifically cerebral cortex hemodynamics.

The device is the first-of-its-kind to leverage neuroimaging to measure brain activity in real-time using a wearable helmet (that resembles a bicycle helmet) during psychedelic treatments.

Cybin, which is sponsoring the study, believes that Kernel Flow can enable the acquisition …

Full story available on Benzinga.com

More FDA Authorizes Cybin Device To Quantify Psychedelics' Effects On The Brain